مقدمه: در سال 2005، چندین گروه شیوع بالایی از جهش V617F (G→ T) را در ژن تیروزین کیناز
JAK2 در نئوپلاسم‌های میلوپرولیفراتیو مزمن (MPNs) شناسایی کردند. در مطالعه‌ی حاضر میزان …‎

Since at least the mid nineteenth century, the diagnosis, therapy, and prognosis of tumors
have primarily been derived from clinicopathological analysis of the tumor. This approach …

Chronic myeloid leukemia (CML) is a progressive, often fatal, hematopoietic neoplasm
characterized by the malignant expansion of pluripotent stem cells in the bone marrow. The …

Dasatinib is a new tyrosine kinase inhibitor which is approved by the FDA for the treatment
of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. Dasatinib …

І 4/60 Л МО-2 4/67 JI МО ц_** 3 4/59 Л Ml+■ 4 4/54 л Ml-5 4/55 л М2+ 6 4/43 л М4-7 4/50 п
мз-8 ч/зз Ї1 М4-9 4/29 п М4-10 4/45 II М4+ 11 Ж/68 п М4-12 4/57 II М5а-13 4/42 п М5Ь-В …

Acquired constitutive activation of protein tyrosine kinases is a central feature of
myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukaemia …

Mit der Entwicklung von Imatinib, einem Inhibitor der Abl-Tyrosinkinase, ist erstmals eine
gezielte Therapie der CML möglich geworden. Bisher stellt jedoch die allogene …

Όπως σε όλες τις νεοπλασίες, έτσι και στις λευχαιμίες υπάρχουν επίκτητες γενετικές βλάβες, οι
οποίες ευθύνονται για την δημιουργία της λευχαιμίας. Οι γενετικές αυτές βλάβες …

This chapter is broadly divided into two parts, one devoted to an introduction to the field of
molecular genetic pathology as a rapidly emerging field of clinical medicine, the other to a …

Most existing chemotherapeutics lack adequate specificity for transformed cells and
therefore have high rates of collateral damage to normal tissue. Moreover, such therapies …